BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets

BridGene Eligible to Receive More Than $700 Million in Potential Upfront and Milestone Payments SAN JOSE, Calif., Jan. 3, 2024 /PRNewswire/ — BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditional “hard-to-drug” targets, announced today a strategic…

Click here to view original post

Advertisement — Advertise with Biotech Networks